Purpose

This study aims to create predictive models of medication non-adherence by using digital markers that identify high risk environmental triggers and behavioral patterns.

Method

Subjects take Abilify MyCite, an FDA approved ingestible sensor system to monitor medication adherence and use the Beiwe app to measure their sociability and mobility.

Collection

Participants take the digital Abilify MyCite tablets for three months while social, behavioral, and cognitive markers using smartphone-based digital phenotyping are simultaneously tracked.

Interpretation

Our team analyzes the data collected from the Abilify MyCite digital tablet system and identifies features of passively (and actively) collected data that are associated with non-adherence and adherence.

Implementation

Our findings will inform the effectiveness and feasibility of a digital tablet as well as future use cases in predicting medication adherence and identifying digital signatures of symptom changes in mental illnesses.

Interested in participating?

Eligibility criteria: ​

• Own a smartphone (Apple or Android)
• 18-65 years old
  
• Clinical diagnosis of schizophrenia, depression, or bipolar disorder
• Currently prescribed Abilify

Study Details:
This study involves 6 visits to the Massachusetts Mental Health Center (75 Fenwood Road, Boston) over 5 months.  
Participants can receive up to $425 for completion of the study. 

Relevant Reading

• Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factorsfor medication nonadherence in patients with schizophrenia: a comprehensivereview of recent literature. The Journal of clinical psychiatry. 2002 Oct.
• Gibson S, Brand SL, Burt S, Boden ZV, Benson O. Understanding treatment non-adherencein schizophrenia and bipolar disorder: a survey of what service users do and why. BMC psychiatry. 2013 Dec;13(1):153.
• Higashi K, Medic G, Littlewood KJ, Diez T, Granstrom O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of non adherence, a systematic literature review. Therapeutic advances in psychopharmacology. 2013 Aug;3(4):200-18.
• Bain EE, Shafner L, Walling DP, Othman AA, Chuang-Stein C, Hinkle J, Hanina A. Useof a novel artificial intelligence platform on mobile devices to assess dosing compliance in a phase 2 clinical trial in subjects with schizophrenia. JMIRmHealth and uHealth. 2017 Feb;5(2).
• BarnettI, Torous J, Staples P, Sandoval L, Keshavan M, Onnela JP. Relapse prediction in schizophrenia through digital phenotyping: a pilot study.Neuropsychopharmacology. 2018 Feb 22:1.

Questions?

Please contact Hannah
hwisnie1@bidmc.harvard.edu
617-667-0035